Bionomics Limited To Present Preclinical Data On BNC105 At AACR-NCI-EORTC International Conference
• Synergistic relationship seen with BNC105 and checkpoint inhibitors in preclinical models of colorectal cancer
• BNC105 also shown to suppress renal, breast and soft tissue sarcoma tumor growth in combination with evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, in preclinical models
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, today announced that preclinical data from ongoing studies of BNC105, its vascular disrupting agent, will be presented during a poster session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held 5-9 November 2015 in Boston, MA.
As reported in the abstracts available online, preclinical results from a study of BNC105 in combination with the hypoxia-activated prodrug evofosfamide (previously known as TH-302) demonstrated encouraging synergistic activity in renal and breast cancer models, as indicated by enhanced tumor growth inhibition over monotherapy. In work completed after abstract submission but included in the poster, the combination of BNC105 and evofosfamide also demonstrated additive activity in a model of soft tissue sarcoma.
Evofosfamide is currently being evaluated in two fully recruited Phase 3 trials for the treatment of locally advanced unresectable or metastatic soft tissue sarcoma and locally advanced unresectable or metastatic pancreatic cancer by Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany.
Bionomics, Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany collaborated on the preclinical evaluations of BNC105 and evofosfamide.
BNC105 was also studied in vivo in combination with antibodies that target PD-1 or CTLA4 in colorectal cancer xenograft models and data showed a synergistic relationship for the combination therapy when looking at inhibition of tumor growth.
Details of the poster presentations are as follows:
Poster Session B: Therapeutics Agents: Other
B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors
Saturday, November 7, 2015, 12:30 PM – 3:30 PM
Exhibit Hall C-D
Poster Session B: Immune Checkpoints
B92: Tubulin-targeting agent BNC105 potentiates the efficacy of Immune checkpoint inhibitors in preclinical models of colorectal cancer
Saturday, November 7, 2015, 12:30 PM – 3:30 PM
Exhibit Hall C-D
Poster Presentations will be available at www.bionomics.com.au following conclusion of the session.
Help employers find you! Check out all the jobs and post your resume.
• BNC105 also shown to suppress renal, breast and soft tissue sarcoma tumor growth in combination with evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, in preclinical models
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, today announced that preclinical data from ongoing studies of BNC105, its vascular disrupting agent, will be presented during a poster session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held 5-9 November 2015 in Boston, MA.
As reported in the abstracts available online, preclinical results from a study of BNC105 in combination with the hypoxia-activated prodrug evofosfamide (previously known as TH-302) demonstrated encouraging synergistic activity in renal and breast cancer models, as indicated by enhanced tumor growth inhibition over monotherapy. In work completed after abstract submission but included in the poster, the combination of BNC105 and evofosfamide also demonstrated additive activity in a model of soft tissue sarcoma.
Evofosfamide is currently being evaluated in two fully recruited Phase 3 trials for the treatment of locally advanced unresectable or metastatic soft tissue sarcoma and locally advanced unresectable or metastatic pancreatic cancer by Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany.
Bionomics, Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany collaborated on the preclinical evaluations of BNC105 and evofosfamide.
BNC105 was also studied in vivo in combination with antibodies that target PD-1 or CTLA4 in colorectal cancer xenograft models and data showed a synergistic relationship for the combination therapy when looking at inhibition of tumor growth.
Details of the poster presentations are as follows:
Poster Session B: Therapeutics Agents: Other
B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors
Saturday, November 7, 2015, 12:30 PM – 3:30 PM
Exhibit Hall C-D
Poster Session B: Immune Checkpoints
B92: Tubulin-targeting agent BNC105 potentiates the efficacy of Immune checkpoint inhibitors in preclinical models of colorectal cancer
Saturday, November 7, 2015, 12:30 PM – 3:30 PM
Exhibit Hall C-D
Poster Presentations will be available at www.bionomics.com.au following conclusion of the session.
Help employers find you! Check out all the jobs and post your resume.